Clinical Trial Update: Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients [Phase 2]

View source ↗

Summary

Phase 2 study of ponatinib (Iclusig) to prevent relapse after allogeneic stem cell transplantation in FLT3-ITD acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED